You are here

  • Home
  • Archive
  • Volume 8, Issue 2
  • Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis

Article metrics

Article menu
XML
Clinical/translational cancer immunotherapy
Original research
Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis

 

Online download statistics by month:

Online download statistics by month: October 2020 to July 2025

AbstractFullPdf
Oct 2020705705242
Nov 202028428491
Dec 202012112140
Jan 202118418484
Feb 202120720753
Mar 202125125157
Apr 202121421434
May 202121721749
Jun 202120120144
Jul 202116916933
Aug 202115315333
Sep 202118118144
Oct 202123323382
Nov 202117817867
Dec 202114614623
Jan 202216116627
Feb 202212213028
Mar 2022484827
Apr 202212813333
May 202214015244
Jun 202215315635
Jul 202216516526
Aug 202216216217
Sep 202213814130
Oct 202214414837
Nov 202210110231
Dec 2022959722
Jan 202312312423
Feb 202313113832
Mar 202316816954
Apr 202311411430
May 202314414441
Jun 202314514530
Jul 202311011120
Aug 202314114350
Sep 202314014026
Oct 202311111241
Nov 202315215229
Dec 202322722924
Jan 2024464722
Feb 2024909023
Mar 2024185186104
Apr 202412212344
May 202410911125
Jun 2024908923
Jul 2024969923
Aug 2024828124
Sep 2024797928
Oct 2024919129
Nov 2024919222
Dec 202411712167
Jan 202511611836
Feb 2025717125
Mar 2025929223
Apr 202510410432
May 2025666627
Jun 2025636320
Jul 2025110
Total841884892330